PBMs began by providing a huge service to payers, but in recent years, they've begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?
Acquisitions that were applauded a few years ago, such as Teva's purchase of Allergan's generic business, now look like lemons.
By allowing companies to claim a 50% tax credit for qualified clinical testing expenses, developing drugs for rare diseases became economically feasible for the first time.
In his first press conference as president-elect, Donald Trump insisted pharma was "getting away with murder" due to expensive drug prices.
It turns out the real goal is going after Washington's favorite whipping boy — high drug prices.
Do you recall what President Trump tweeted right after Merck's Kenneth Frazier resigned from his American Manufacturing Council?
AI complements what we in pharma have always done best — respond to medical needs quickly and find solutions.
The coming digital revolution will change a lot of things, but I guarantee this: It won't replace the importance of the patient-physician relationship.
If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.
Healthcare marketing has a head start in grooming women leaders. But it's by no means a fait accompli.